High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancer.
Sikand, Kanwal A
Shanks, Jonathan H
Thistlethwaite, Fiona C
Hawkins, Robert E
AffiliationDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
MetadataShow full item record
AbstractMetastatic renal cancer remains hard to treat and the treatment is generally palliative. However, high-dose interleukin-2 (HD IL-2) produced 5% to 10% complete remissions and most of these were durable. With the advent of newer treatments with less toxicity, the role of HD IL-2 is uncertain. We present here a case series of 72 patients with metastatic renal cancer given first-line treatment with HD IL-2. From 2003 to 2006, the patients were offered treatment with HD IL-2 irrespective of their histologic features (retrospective cohort). From 2006 to 2008, the treatment was only offered to patients after stratification into risk groups based on histologic criteria (prospective cohort). In the early series, the response rate to HD IL-2 was 27% (8/30), but with prospective stratification of patients by histology the response rate was 52% (21/40) in the group with favorable histologic features. Combining outcome for all patients with the favorable histology (including those identified retrospectively) 49% (28/57) responded with 25% (14/57) achieving a complete remission and these seem durable. Patients with metastatic renal cancer should be carefully assessed for their suitability to undergo treatment with first-line systemic therapy with HD IL-2 as in carefully selected patients it has a high-rate response and durable remissions.
CitationHigh-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancer. 2011, 34 (1):107-12 J Immunother
JournalJournal of Immunotherapy
- Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.
- Authors: Rosenberg SA, Yang JC, White DE, Steinberg SM
- Issue date: 1998 Sep
- Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
- Authors: Negrier S, Maral J, Drevon M, Vinke J, Escudier B, Philip T
- Issue date: 2000 Feb
- Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
- Authors: Lee DS, White DE, Hurst R, Rosenberg SA, Yang JC
- Issue date: 1998 Mar-Apr
- Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer.
- Authors: Acquavella N, Kluger H, Rhee J, Farber L, Tara H, Ariyan S, Narayan D, Kelly W, Sznol M
- Issue date: 2008 Jul-Aug
- An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer.
- Authors: Yang JC, Rosenberg SA
- Issue date: 1997 Dec